Published in J Virol on May 01, 1992
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol (1995) 2.91
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol (1995) 2.45
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck (2008) 2.28
Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol (2000) 2.21
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol (1993) 1.94
Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol (1997) 1.90
Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.89
Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A (1995) 1.89
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol (1999) 1.80
Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol (2003) 1.74
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer (1996) 1.70
Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol (1993) 1.69
Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol (1997) 1.64
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol (1992) 1.61
Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia (2009) 1.59
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol (1995) 1.58
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol (1993) 1.58
Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol (1995) 1.57
Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A (2000) 1.56
Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol (1998) 1.55
Microbiome and malignancy. Cell Host Microbe (2011) 1.45
Emerging treatment options for nasopharyngeal carcinoma. Drug Des Devel Ther (2013) 1.44
Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol (1999) 1.41
Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog (2010) 1.40
Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol (2000) 1.38
Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol (1994) 1.34
Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol (2004) 1.34
Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol (1999) 1.33
Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci U S A (2004) 1.32
Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer (2014) 1.32
Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol (1993) 1.31
Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol (2009) 1.31
Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol (1997) 1.28
The Epstein-Barr virus and its association with human cancers. Mol Pathol (1999) 1.26
Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol (2000) 1.26
5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J Virol (1995) 1.26
Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One (2011) 1.22
Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol (2005) 1.19
Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer (2003) 1.19
Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates. J Virol (1999) 1.13
Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol (2002) 1.13
Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol (2005) 1.12
The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol (2000) 1.12
Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol (1999) 1.07
Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One (2007) 1.07
Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol (1999) 1.06
The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol (1998) 1.06
Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci (1994) 1.06
Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture. J Virol (1993) 1.05
Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9. J Virol (2012) 1.03
The role of EBV in post-transplant malignancies: a review. J Clin Pathol (2000) 1.02
The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells. Am J Pathol (1997) 1.02
Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol (2003) 0.99
Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol Pathol (1999) 0.99
The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol (2005) 0.98
Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol (2012) 0.98
Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. Int J Cell Biol (2012) 0.98
Establishment and maintenance of long-term murine gammaherpesvirus 68 latency in B cells in the absence of CD40. J Virol (2005) 0.96
Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer (2012) 0.94
Specific methylation patterns in two control regions of Epstein-Barr virus latency: the LMP-1-coding upstream regulatory region and an origin of DNA replication (oriP). J Virol (1998) 0.93
Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray. J Infect Dis (2011) 0.93
Establishment and characterization of a human Epstein-Barr virus-associated gastric carcinoma in SCID mice. J Virol (1998) 0.93
EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J (2005) 0.92
Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J Clin Pathol (1996) 0.92
Epstein-Barr virus infection of human astrocyte cell lines. J Virol (1999) 0.91
The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer (2001) 0.90
Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am J Epidemiol (2014) 0.90
Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αv-integrin membrane translocation. J Virol (2012) 0.90
Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology (2014) 0.89
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells. PLoS One (2013) 0.87
Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL/6J mice. J Virol (2008) 0.87
Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation. Oncogene (2010) 0.87
Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol (2006) 0.87
Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol (1999) 0.87
Effect of Epstein-Barr virus infection on global gene expression in nasopharyngeal carcinoma. Funct Integr Genomics (2006) 0.86
BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator. Rev Med Virol (2013) 0.85
Expression of Epstein-Barr virus encoded latent genes in nasal T cell lymphomas. J Clin Pathol (1996) 0.84
Expression of Epstein-Barr virus (EBV)-encoded latent membrane proteins and STAT3 activation in nasopharyngeal carcinoma. Virchows Arch (2006) 0.84
Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy. Int J Mol Sci (2013) 0.83
Nucleic acid sequence-based amplification, a new method for analysis of spliced and unspliced Epstein-Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. J Clin Microbiol (1998) 0.83
Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients. Clin Vaccine Immunol (2010) 0.83
Upregulation of endocan by Epstein-Barr virus latent membrane protein 1 and its clinical significance in nasopharyngeal carcinoma. PLoS One (2013) 0.82
Establishment and characterization of a novel nasopharyngeal carcinoma cell line (SUNE2) from a Cantonese patient. Chin J Cancer (2011) 0.82
Chick Chorioallantoic Membrane Assay: A 3D Animal Model for Study of Human Nasopharyngeal Carcinoma. PLoS One (2015) 0.82
Epstein-Barr virus latent membrane protein 2 effects on epithelial acinus development reveal distinct requirements for the PY and YEEA motifs. J Virol (2013) 0.82
Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol (2015) 0.81
Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. Chin J Cancer (2016) 0.81
Epstein-Barr virus latent membrane protein 2A contributes to anoikis resistance through ERK activation. J Virol (2013) 0.81
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A (1984) 10.91
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol (1986) 6.00
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A (1983) 4.94
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA. Proc Natl Acad Sci U S A (1982) 4.23
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J (1988) 3.69
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol (1989) 3.09
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
EBV gene expression in an NPC-related tumour. EMBO J (1989) 2.94
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol (1985) 2.82
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci U S A (1991) 2.61
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc Natl Acad Sci U S A (1990) 2.58
Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer (1988) 2.46
Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol (1990) 2.43
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell (1990) 2.20
The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol (1989) 1.59
Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells. Nucleic Acids Res (1991) 1.57
Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol (1983) 1.57
Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera. J Virol (1990) 1.56
Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol (1991) 1.45
Alternative splicing dictates translational start in Epstein-Barr virus transcripts. EMBO J (1990) 1.38
Epstein-Barr virus-specific transcription in normal and malignant nasopharyngeal biopsies and in lymphocytes from healthy donors and infectious mononucleosis patients. J Gen Virol (1987) 1.16
Analysis of human papillomavirus type 16 E6-E7 transcription in cervical carcinomas and normal cervical epithelium using the polymerase chain reaction. J Gen Virol (1990) 1.01
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol (1999) 3.36
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer (1978) 2.81
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med (1997) 2.76
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. Int J Cancer (1982) 2.55
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med (1988) 2.52
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science (1993) 2.28
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer (1985) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 2.17
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Piperacillin therapy for serious bacterial infections. Am J Med (1980) 2.14
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med (1980) 2.11
A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med (1972) 2.11
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol (1984) 2.01
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun (1991) 1.97
Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer (1989) 1.97
Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol (1989) 1.92
Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med (1977) 1.90
HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature (1980) 1.90
Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy (1978) 1.88
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature (1985) 1.86
Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med (1977) 1.86
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
LMP1 structure and signal transduction. Semin Cancer Biol (2001) 1.85
Functional role of antibody against "core" glycolipid of Enterobacteriaceae. J Clin Invest (1975) 1.80
Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol (1997) 1.78
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer (1989) 1.76
Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol (1999) 1.76
Infectious complications of neoplastic disease. Med Clin North Am (1971) 1.75
EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol (2001) 1.75
Infectious complications of human bone marrow transplantation. Medicine (Baltimore) (1979) 1.74
Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene (1997) 1.74